# US 2026/0184772 A1 · Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0184772 A1
- Document ID: US20260184772A1
- Status: Published application
- Kind: A1
- Application number: 19/265,582
- Filed: 2025-07-10
- Published: 2026-07-02
- Earliest claimed: 2011-09-19
- Assignees: Axon Neuroscience SE
- Applicants: Axon Neuroscience SE
- Inventors: Michal NOVÁK; Eva KONTSEKOVÁ; Branislav KOVÁCECH; Norbert ŽILKA
- Web page: https://patentgrep.com/patent/US20260184772A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/1709: {from mammals}
- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- G01N 2800/2821: Alzheimer
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

## Claims

### Claim at position 1

1-116. (canceled)

### Claim 117

A fusion protein, comprising:
a. an immunogenic peptide consisting of the amino acid sequence of KDNIKHVPGGGS (SEQ ID NO: 108) or CKDNIKHVPGGGS (SEQ ID NO: 218); and
b. a carrier.

### Claim 118 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide is linked to the carrier at the amino terminus of the immunogenic peptide.

### Claim 119 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide is linked to the carrier at the carboxyl terminus of the immunogenic peptide.

### Claim 120 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide is linked to the carrier at an amino acid residue of the immunogenic peptide that is between the amino and carboxyl termini.

### Claim 121 (depends on 117)

The fusion protein of claim 117, comprising more than one copy of the immunogenic peptide.

### Claim 122 (depends on 117)

The fusion protein of claim 117, wherein the carrier comprises one or more of serum albumin; keyhole limpet hemocyanin (KLH); an immunoglobulin molecule; ovoglobulin; thyroglobulin; ovalbumin; tetanus toxoid; a toxoid from diphtheria, E. coli, cholera, or H. pylori; an attenuated toxin derivative; IL-1α; IL-1β; IL-2; IFN-γ; IL-10; GM-CSF; MIP1α; MIP1β; and RANTES.

### Claim 123 (depends on 122)

The fusion protein of claim 122, wherein the carrier comprises KLH.

### Claim 124 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide consists of the amino acid sequence of KDNIKHVPGGGS (SEQ ID NO: 108).

### Claim 125 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide consists of the amino acid sequence of CKDNIKHVPGGGS (SEQ ID NO: 218).

### Claim 126 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide consists of the amino acid sequence of KDNIKHVPGGGS (SEQ ID NO: 108) and the carrier comprises keyhole limpet hemocyanin.

### Claim 127 (depends on 117)

The fusion protein of claim 117, wherein the immunogenic peptide consists of the amino acid sequence of CKDNIKHVPGGGS (SEQ ID NO: 218) and the carrier comprises keyhole limpet hemocyanin.

### Claim 128 (depends on 117)

A pharmaceutical composition comprising the fusion protein of claim 117 and a pharmaceutically acceptable carrier, diluent, adjuvant, or a combination thereof.

### Claim 129 (depends on 128)

The pharmaceutical composition of claim 128, wherein the adjuvant is aluminum hydroxide.

### Claim 130 (depends on 117)

A pharmaceutical composition comprising the fusion protein of claim 117 and aluminum hydroxide.

### Claim 131 (depends on 126)

A pharmaceutical composition comprising the fusion protein of claim 126 and aluminum hydroxide.
